Aclaris Therapeutics Debt 2024

Aclaris Therapeutics Aktienanalyse

What does Aclaris Therapeutics do?

Aclaris Therapeutics Inc was founded in 2012 and is based in Wayne, Pennsylvania. The company focuses on the development and marketing of innovative solutions for the treatment of skin problems and other diseases that significantly impact the quality of life of those affected. Aclaris' business model is based on the research and development of new therapies that address various medical problems and conditions. The company employs a combination of internal research projects and the acquisition of promising products and pipeline assets from third-party companies. Aclaris is divided into different business segments that focus on various medical issues and conditions. One important area is dermatology, where the company has developed several innovative products and therapies. This includes RHOFADE® (Oxymetazoline Hydrochloride), a topical medication for the treatment of rosacea. The novel product A-101, used for the treatment of seborrheic keratosis, has also been established in the market. In the field of oncological dermatology, Aclaris has a promising pipeline focused on the development of drugs for the treatment of actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and melanoma. The company collaborates closely with scientists and research institutions to develop innovative solutions that can revolutionize the pharmaceutical market. Another area that Aclaris focuses on is immunology, including the development of new therapies for the treatment of inflammatory diseases such as alopecia areata, an autoimmune disease that causes hair loss. Aclaris has already made significant progress in this area and is conducting clinical studies to demonstrate the effectiveness of its products in treating this condition. In addition to the development of innovative therapies, Aclaris also collaborates closely with other companies and research institutions to develop platform technologies that can accelerate and simplify the development of new drugs. This includes state-of-the-art analytical methods and the development of new molecules that specifically target certain diseases. Aclaris' business model has proven successful in recent years. The company combines internal research projects with the acquisition of promising pipeline assets from third-party companies to expand its portfolio and pipeline. This approach allows Aclaris to quickly respond to changing market conditions and patient needs, positioning themselves as a leading player in the pharmaceutical market. Aclaris' products have already improved many lives and successfully treated numerous patients with various medical problems. The company aims to achieve sustainable improvement in the quality of life of patients and continuously develop new innovative solutions to secure a leading position in the highly competitive pharmaceutical market. Aclaris Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Aclaris Therapeutics's Debt Structure

Aclaris Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Aclaris Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Aclaris Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Aclaris Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Aclaris Therapeutics stock

What is the debt of Aclaris Therapeutics this year?

Aclaris Therapeutics has a debt level of -39.88 USD this year.

What was the debt of Aclaris Therapeutics compared to the previous year?

The debt of Aclaris Therapeutics has increased by -11.97% compared to the previous year dropped.

What are the consequences of high debt for investors in Aclaris Therapeutics?

High debt can pose a risk for investors of Aclaris Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Aclaris Therapeutics?

Low debt means that Aclaris Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Aclaris Therapeutics affect the company?

An increase in debt of Aclaris Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Aclaris Therapeutics affect the company?

A reduction in debt of Aclaris Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Aclaris Therapeutics?

Some factors that can influence the debt of Aclaris Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Aclaris Therapeutics so important for investors?

The debts of Aclaris Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Aclaris Therapeutics take to change the debt?

To change the debt, Aclaris Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Aclaris Therapeutics pay?

Over the past 12 months, Aclaris Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aclaris Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aclaris Therapeutics?

The current dividend yield of Aclaris Therapeutics is .

When does Aclaris Therapeutics pay dividends?

Aclaris Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aclaris Therapeutics?

Aclaris Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aclaris Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aclaris Therapeutics located?

Aclaris Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aclaris Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aclaris Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did Aclaris Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Aclaris Therapeutics in the year 2023?

In the year 2023, Aclaris Therapeutics distributed 0 USD as dividends.

In which currency does Aclaris Therapeutics pay out the dividend?

The dividends of Aclaris Therapeutics are distributed in USD.